Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2022 Jul 20;22(10):718–725. doi: 10.1016/j.clml.2022.07.010

Figure 1. T-ALL Biology.

Figure 1.

T-ALL can be divided into groups based on genetic alterations that lead to dysregulation of potentially targetable functional pathways (outer ring) or based on increased expression of different transcription factors (inner ring). Percents are frequencies in the TARGET T-ALL cohort.30 High risk (<70% 5-year event-free survival), Intermediate risk (70–90%), Low risk (>90%) – rates are not adjusted for MRD. Adapted from Teachey and Pui, Lancet Oncology 2019.2